证券代码：603139 证券简称：康惠制药 公告编号：2025-043 陕西康惠制药股份有限公司 关于为控股子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | 被担保人名称 | | 四川春盛药业集团股份有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 500 | 万元 | | | 担 保 对象 | 实际为其提供的担保余额 | 2,890 | 万元 | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 | □否 | □不适用：_________ | 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额（万元） | 11,871.84 | | 对外担保总额占上市公司最近一期经审计净资产的比例（%） | 13.85 | 一、担保情况概述 （一） 担 ...

Group 1 - Bailitianheng's innovative biopharmaceutical izabren (EGFR×HER3 dual-target ADC) has received approval for a Phase II clinical trial to treat advanced kidney cancer in combination with lenvatinib and pembrolizumab, potentially enhancing anti-tumor effects and addressing unmet needs in kidney cancer treatment [1] - Kanghui Pharmaceutical is involved in a legal dispute with Hubei Kelaivi regarding equity repurchase payments, with the latter appealing a first-instance ruling that ordered payment of 2 million yuan and 35.994 million yuan, highlighting risks in performance guarantees and repurchase clauses in pharmaceutical mergers [2] - *ST Suwu has announced an expected net loss of 60 million to 40 million yuan for the first half of 2025, primarily due to significant impairment provisions for trade receivables, indicating potential delisting risks if the company cannot return to profitability [3] - East China Pharmaceutical is exploring early projects targeting fat reduction and muscle health, aiming to capitalize on the global trend of GLP-1 drugs, although the projects are still in early exploration stages with significant uncertainties [4] - XW003 injection by Xianweida has initiated a new Phase II clinical trial comparing its efficacy and safety against semaglutide in obese patients, which could validate its unique cAMP-biased GLP-1 mechanism and accelerate entry into the weight loss market [5]

Group 1 - The company expects a net profit attributable to shareholders of approximately -38 million yuan for the first half of 2025, indicating a loss [2][4] - The estimated net profit attributable to shareholders, excluding non-recurring gains and losses, is approximately -41 million yuan for the same period [5] - The performance forecast period is from January 1, 2025, to June 30, 2025 [3] Group 2 - For the first half of 2024, the total profit was -9.88 million yuan, with a net profit attributable to shareholders of -8.70 million yuan [7] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -15.99 million yuan [7] - The earnings per share for the first half of 2024 was -0.09 yuan [8] Group 3 - The primary reasons for the expected loss include increased costs and expenses due to changes in pharmaceutical policies and industry environment [9] - The company is actively adjusting its business strategy to focus on sales and expand its market presence in community hospitals, clinics, and pharmacies [9] - The subsidiary, Shaanxi Youbang Biomedical Technology Co., Ltd., is experiencing significant depreciation and financing costs, along with unfavorable market conditions, contributing to the overall loss [9] Group 4 - The company has received a civil appeal regarding a lawsuit related to a share repurchase agreement, with the amount involved being approximately 37.99 million yuan plus interest [16] - The company is currently in the stage of receiving the appeal, and the outcome of the lawsuit remains uncertain [14][16] - The company will fulfill its information disclosure obligations based on the progress of the lawsuit [16]

证券代码：603139 证券简称：康惠制药 公告编号：2025-042 陕西康惠制药股份有限公司 关于收到《民事上诉状》暨诉讼进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 案件所处的诉讼阶段：收到上诉状 ● 是否会对上市公司损益产生影响：因目前仅收到上诉状，二审受理及具 体开庭时间尚未明确，诉讼结果存在不确定性，公司暂无法准确判断本次诉讼进 展对公司本期或期后利润的影响。 一、本次诉讼的基本情况 陕西康惠制药股份有限公司（以下简称"公司"）就要求与湖北科莱维生物 药业有限公司（以下简称"科莱维"）支付股权回购定金及股权回购款事项于 2024年9月向陕西省咸阳市秦都区人民法院提起诉讼，具体内容详见公司于2024 年 9 月 21 日在上海证券交易所网站（www.sse.com.cn）披露的《陕西康惠制药 股份有限公司关于科莱维回购公司所持其 42.8725%股权进展暨公司提起诉讼的 公告》（公告编号：2024-048）。 2025 年 5 月 16 日，公司收到陕西省咸阳市秦都区人民法院《民事判 ...

[Performance Forecast Overview](index=1&type=section&id=Performance%20Forecast%20Overview) The company anticipates a significant loss for the first half of 2025, with specific net profit figures provided for both attributable and non-recurring adjusted results [Key Highlights](index=1&type=section&id=Key%20Highlights) Shaanxi Kanghui Pharmaceutical Co., Ltd. expects a loss for the first half of 2025, with net profit attributable to shareholders estimated at approximately -38 million RMB and net profit attributable to shareholders after deducting non-recurring gains and losses estimated at approximately -41 million RMB Estimated Financial Performance for H1 2025 | Indicator | Estimated Amount (Million RMB) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -38 | | Net Profit Attributable to Parent Company Shareholders After Deducting Non-Recurring Gains/Losses | -41 | | Impact of Non-Recurring Gains/Losses | 2.6 | - The company anticipates a **loss for the first half of 2025**[3](index=3&type=chunk) [Current Period Performance Forecast](index=1&type=section&id=Current%20Period%20Performance%20Forecast) The company specified the performance forecast period for the first half of 2025 as January 1 to June 30, reiterated the projected loss figures, and emphasized that this forecast is a preliminary estimate unaudited by an accounting firm - The performance forecast period is **January 1, 2025, to June 30, 2025**[4](index=4&type=chunk) Key Estimated Financial Indicators for H1 2025 | Indicator | Estimated Amount (Million RMB) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -38 | | Net Profit Attributable to Parent Company Shareholders After Deducting Non-Recurring Gains/Losses | -41 | - This performance forecast is a preliminary estimate based on the company's operating conditions and has **not been audited by an accounting firm**[6](index=6&type=chunk) [H1 2024 Performance Review](index=1&type=section&id=H1%202024%20Performance%20Review) This section reviews the company's financial performance for the first half of 2024, highlighting the previously incurred losses as a comparative context [H1 2024 Performance Details](index=1&type=section&id=H1%202024%20Performance%20Details) The company disclosed its financial data for the first half of 2024, indicating a prior loss state, which serves as a comparative baseline for the current period's projected loss, with net profit attributable to parent company shareholders at **-8.7020 million RMB** H1 2024 Financial Performance | Indicator | H1 2024 Amount (Million RMB) | | :--- | :--- | | Total Profit | -9.8818 | | Net Profit Attributable to Parent Company Shareholders | -8.7020 | | Net Profit After Deducting Non-Recurring Gains/Losses | -15.9866 | | Earnings Per Share (RMB) | -0.09 | [Analysis of Main Reasons for Projected Loss](index=2&type=section&id=Analysis%20of%20Main%20Reasons%20for%20Projected%20Loss) This section analyzes the primary factors contributing to the projected loss, including increased parent company costs and significant losses from a controlled subsidiary [Increase in Parent Company Costs and Expenses](index=2&type=section&id=Increase%20in%20Parent%20Company%20Costs%20and%20Expenses) Influenced by pharmaceutical policies and industry conditions, the parent company actively adjusted its operating strategy, expanded sales channels (including secondary and tertiary terminals), and optimized product structure (increasing sales of agency products), leading to a significant increase in costs and expenses in H1 2025 compared to the previous year, thus impacting overall performance - Affected by pharmaceutical policies and industry environment, the company actively adjusted its operating strategy, maintaining a **sales-centric approach**[8](index=8&type=chunk) - The company continues to consolidate hospital sales and vigorously expand **secondary and tertiary terminal sales** such as community hospitals, clinics, and pharmacies[8](index=8&type=chunk) - The company adjusted its sales product structure, increasing sales of agency products, which led to a **significant increase in costs and expenses** in H1 2025 compared to the previous year[8](index=8&type=chunk) [Impact of Losses from Controlled Subsidiary](index=2&type=section&id=Impact%20of%20Losses%20from%20Controlled%20Subsidiary) Controlled subsidiary Shaanxi Youbang Biomedical Technology Co., Ltd. incurred significant fixed asset depreciation and financing loan interest expenses, coupled with unexpected product market supply-demand changes leading to lower-than-expected revenue, resulting in substantial losses in H1 2025 and a significant impact on the company's current period performance - Controlled subsidiary Shaanxi Youbang Biomedical Technology Co., Ltd. incurred **significant fixed asset depreciation and financing loan interest expenses**[8](index=8&type=chunk) - Shaanxi Youbang's product market supply and demand relationship is highly volatile, leading to **lower-than-expected product revenue**[8](index=8&type=chunk) - Shaanxi Youbang continued to incur **substantial losses in H1 2025**, impacting the company's current period performance[8](index=8&type=chunk) [Risk Warning and Disclosures](index=2&type=section&id=Risk%20Warning%20and%20Disclosures) This section provides crucial risk warnings and disclosures, emphasizing the preliminary nature of the financial forecast and advising investors to exercise caution [Risk Warning](index=2&type=section&id=Risk%20Warning) The company reiterates that this performance forecast is a preliminary calculation based on the finance department's professional judgment and has not been audited by a certified public accountant, reminding investors to be aware of potential investment risks - This performance forecast is a preliminary calculation by the company's finance department based on its professional judgment and has **not yet been audited by a certified public accountant**[9](index=9&type=chunk) [Other Disclosures](index=2&type=section&id=Other%20Disclosures) The company reminds investors that the performance forecast data is only a preliminary calculation, and the final accurate financial data will be subject to the company's officially disclosed '2025 Semi-Annual Report,' reiterating investment risks - The performance forecast data above is only preliminary; the **final accurate financial data will be based on the company's officially disclosed '2025 Semi-Annual Report'**[10](index=10&type=chunk) - Investors are kindly reminded to **pay attention to investment risks**[10](index=10&type=chunk)

Core Points - The controlling shareholder of Xi'an Kanghui Pharmaceutical Co., Ltd. will change to Yuehe Zhichuang after the completion of the share transfer and related governance adjustments [1][2] - The share transfer involves 21,973,600 shares, representing 22% of the total shares, at a price of RMB 24.70 per share [1][2] - The actual controllers will be Li Hongming and Wang Xuefang after the governance adjustments are completed [2][3] Share Transfer Details - The share transfer has been completed, with the shares transferred to Yuehe Zhichuang on July 8, 2025 [2] - Before the transfer, Kanghui Holdings held 36,706,237 shares (36.75%), which will reduce to 14,732,637 shares (14.75%) after the transfer [2] - Yuehe Zhichuang will hold 21,973,600 shares (22%) post-transfer [2] Governance Changes - The company will proceed with the adjustment of board members and the appointment of executives as per the supplementary agreement [2][3] - The final implementation of the governance changes remains uncertain until the adjustments are completed [3]

陕西康惠制药股份有限公司 证券代码：603139 证券简称：康惠制药 公告编号：2025-040 近日，康惠控股与悦合智创就本次股份转让已办理完成相关过户登记手续， 并取得了中国证券登记结算有限责任公司上海分公司出具的《证券过户登记确认 书》，康惠控股所持有的公司无限售条件流通股 21,973,600 股股份已过户登记至 悦合智创名下，过户日期为 2025 年 7 月 8 日。 关于控股股东协议转让公司股份完成过户登记 暨控制权拟发生变更的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 本次权益变动相关事项已在中国证券登记结算有限责任公司上海分公司 办理完毕股份过户登记手续。 本次权益变动事项尚待进行公司治理事宜调整，待公司治理事宜调整完 毕之日起，公司控股股东将变更为悦合智创，实际控制人将变更为李红明、王雪 芳夫妇，前述事项的最终实施结果尚存在不确定性，敬请投资者注意投资风险。 一、本次权益变动情况概述 2025 年 3 月 20 日, 陕西康惠制药股份有限公司（以下简称"康惠制药"、"上 市公司"） ...

Group 1 - *ST San Sheng (002742.SZ): The controlling shareholder Pan Xianwen's 32.2 million shares have been transferred, accounting for 7.30% of the total share capital, reducing his holding from 17.26% to 16.75, with no change in company control [1] - Aikang Co., Ltd. (300889.SZ): Shareholders Zhang Fengbin and Feng Renrong reduced their holdings by a total of 1.76 million shares, accounting for 1.06% of the total share capital, completing the reduction plan [1] - Allianz Ruishi (301042.SZ): Director Shen Lei reduced his holdings by 98,700 shares, accounting for 0.14% of the total share capital, with the reduction plan period ending [1] Group 2 - Baotong Technology (300031.SZ): Controlling shareholder Bao Zhifang and director Tang Yu plan to reduce their holdings by up to 8.3749 million shares and 1.526988 million shares, accounting for no more than 2% and 0.36% of the total share capital, respectively [2] - Biyiwei (688045.SH): Shareholders Fang Guang Erqi and Yuan Chengjun plan to reduce their holdings by up to 139,680 shares and 69,840 shares, accounting for no more than 2% and 1% of the total share capital, respectively [2] - Chahua Co., Ltd. (603615.SH): Shareholder Shenzhen Hanjinliang reduced 2.397 million shares, accounting for 0.99% of the total share capital, completing the reduction plan [2] Group 3 - Dacai Co., Ltd. (605287.SH): Shareholder Qingdao Dikuang Chanquan Development Co., Ltd. reduced 3.64 million shares, accounting for 2.60% of the total share capital, completing the reduction plan [3] - Dize Pharmaceutical (688192.SH): Vice President Zhang Shiying reduced 161,550 shares, accounting for 0.0035% of the total share capital, completing the reduction plan [3] - Fuhan Micro (300613.SZ): Controlling shareholder's concerted action party plans to reduce up to 6.90208 million shares, accounting for 3% of the total share capital [3] Group 4 - Guanghuan Xinwang (300383.SZ): Directors and vice presidents plan to reduce a total of up to 720,476 shares, accounting for no more than 0.04% of the total share capital [4] - Hanyu Group (300403.SZ): Director and Vice President Wu Geming plans to reduce up to 1 million shares, accounting for 0.1658% of the total share capital [4] - Haosen Intelligent (688529.SH): Shareholders plan to reduce a total of up to 3 million shares, accounting for 1.7838% of the total share capital [4] Group 5 - Huilong New Materials (301057.SZ): Controlling shareholder's concerted action party plans to reduce up to 3.482902 million shares, accounting for 3% of the total share capital excluding repurchased shares [5] - Huitong Co., Ltd. (688219.SH): Shareholder Tong'an Fund reduced 4.667815 million shares, accounting for 0.93% of the total share capital, completing the reduction plan [5] Group 6 - Jiangsu Shentong (002438.SZ): Shareholder Huzhou Fenglin Huoshan Equity Investment Partnership reduced a total of 14.205 million shares, accounting for 2.798808% of the total share capital, completing the reduction plan [6] - Jiangtian Chemical (300927.SZ): Shareholder Jiangshan Co., Ltd. reduced 1.3265 million shares, accounting for 0.92% of the total share capital [6] - Jin Sanjiang (301059.SZ): Shareholder Guangzhou Saina reduced 104,900 shares, accounting for 0.05% of the total share capital, completing the reduction plan [6] Group 7 - Jingxue Energy (301010.SZ): Controlling shareholder's concerted action party reduced 1.08 million shares, accounting for 1% of the total share capital, completing the reduction plan [7] - Jiuwu High-Tech (300631.SZ): Vice President Wang Xiaohu and Cheng Junjun plan to reduce up to 18,900 shares and 5,000 shares, accounting for no more than 0.1511% and 0.04% of the total share capital, respectively [7] - Kanghui Pharmaceutical (603139.SH): Shareholder Shanghai Sailoxian plans to reduce up to 2.9964 million shares, accounting for 3% of the total share capital [7] Group 8 - Meino Biological (301156.SZ): Shareholder's concerted action party reduced 1.297029 million shares, accounting for 0.92% of the total share capital, completing the reduction plan [8] - Minfa Aluminum Industry (002578.SZ): Shareholder Huang Tianhuo reduced 6.6702 million shares, accounting for 0.71% of the total share capital, reducing his holding to 4.9963% [8] - Nuo Puxin (002215.SZ): Directors and senior management plan to reduce a total of up to 1.8607 million shares, accounting for no more than 0.185% of the total share capital [8] Group 9 - Entropy Technology (301330.SZ): Shareholders reduced a total of 4,693,864 shares, accounting for 1.9556% of the total share capital, completing the reduction plan [9] - Shengbang Co., Ltd. (301233.SZ): Supervisor Hu Jilin plans to reduce up to 5,650 shares, accounting for 0.0111% of the total share capital [9] - Shudao Equipment (300540.SZ): Senior management did not reduce their shares, and the reduction plan period has ended [9] Group 10 - Tongyu Communications (002792.SZ): Controlling shareholder and actual controller Shi Guiqing plans to reduce up to 15,653,487 shares, accounting for 2.9963% of the total share capital [10] Group 11 - Wuzhou Xinchun (603667.SH): Senior management plans to reduce a total of up to 22,500 shares, accounting for no more than 0.0061%, 0.0067%, and 0.0037% of the total share capital [11] - New Sharp Co., Ltd. (688257.SH): Senior management plans to reduce up to 750,000 shares, accounting for no more than 0.2971% of the total share capital [11] - New Hope (000876.SZ): Senior management reduced 225,000 shares, accounting for 0.005% of the total share capital, completing the reduction plan [11] Group 12 - Youke De (688158.SH): Shareholder Zhongyi Capital reduced 882,766 shares, accounting for 0.19% of the total share capital, completing the reduction plan [12] - Changqing Technology (001324.SZ): Shareholders reduced a total of 4,165,050 shares, accounting for 3.00% of the total share capital, completing the reduction plan [12] - Changxin Bochuang (300548.SZ): Shareholders plan to reduce up to 8.6 million shares, accounting for 2.95% of the total share capital [12] Group 13 - Zhongfu Industrial (600595.SH): Shareholder Henan Yicheng Chuangtou plans to reduce up to 40 million shares, accounting for 1% of the total share capital [13] - Zhuhai Ming Technology (300232.SZ): Controlling shareholder Lin Mingfeng plans to reduce up to 21,722,009 shares, accounting for 1.99% of the total share capital [13] - Zhuoyi Information (688258.SH): Employee shareholding platform plans to reduce up to 2,271,445 shares, accounting for no more than 1.88% of the total share capital [13]

Summary of Key Points Core Viewpoint - The announcement details a share reduction plan by a major shareholder, Shanghai Sailoxian Enterprise Management Consulting Co., Ltd., which holds 4% of the total shares of Xi'an Kanghui Pharmaceutical Co., Ltd. The plan involves reducing up to 2,996,400 shares, representing 3% of the company's total shares, over a specified period. Group 1: Shareholder Information - The shareholder, Shanghai Sailoxian, holds 3,995,200 shares, accounting for 4% of the total share capital of the company [1][2] - The shares were acquired through an agreement transfer [2] Group 2: Reduction Plan Details - The reduction plan allows for a maximum of 2,996,400 shares to be sold, which is up to 3% of the total shares [1][2] - The reduction will occur through two methods: a maximum of 998,800 shares via centralized bidding and up to 1,997,600 shares through block trading [2] - The planned reduction period is from July 29, 2025, to October 26, 2025 [2] Group 3: Purpose and Conditions - The reason for the reduction is stated as necessary for the shareholder's own business development plans [2] - The implementation of the reduction plan is subject to market conditions and the company's stock price [2][3]

Core Viewpoint - Several listed companies in the Shanghai and Shenzhen markets have announced significant developments, including management changes, stock trading fluctuations, and major contracts, which may present investment opportunities and risks for investors [2]. Group 1: Management Changes and Legal Issues - Scanda's chairman and general manager, Li Yuejie, along with director Zhu Chuncheng, have been subjected to criminal coercive measures due to alleged violations related to information disclosure [3]. - Longhong High-Tech is planning to acquire 100% equity of Guangxi Changke, leading to a stock suspension for up to 10 trading days [6]. Group 2: Stock Trading and Performance - New Asia Electronics reported abnormal stock trading with a cumulative price deviation exceeding 20% over three days, while confirming that its operations are normal and consistent with previously disclosed share reduction plans [5]. - ST Tiexin announced the removal of risk warnings and a name change, which will increase the trading limit from 5% to 10% [8]. Group 3: Financial Performance Forecasts - Industrial Fulian expects a net profit increase of 36.84% to 39.12% year-on-year for the first half of 2025, driven by a surge in AI-related business [18]. - Huayou Cobalt anticipates a net profit increase of 55.62% to 67.59% for the same period, benefiting from integrated operations and rising cobalt prices [19]. - Guoli Co. forecasts a staggering net profit increase of 130.91% to 158.08% for the first half of 2025, attributed to new product and market expansions [20]. - Bangji Technology expects a net profit increase of 166.77% to 200.91%, driven by increased sales from direct sales channels [21]. - Lier Chemical predicts a net profit increase of 185.24% to 196% due to rising product sales and cost reduction efforts [25]. Group 4: Major Contracts and Projects - Huadian Science and Technology signed significant contracts worth approximately RMB 25.16 billion for coal handling and transportation systems [41]. - Aerospace Engineering is the first candidate for a project with a bid of RMB 23.92 billion for a coal gasification facility [43].